Biohaven Ltd. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months
Biohaven Ltd. (BHVN) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months of $239.00 million as of 2025-06-30, per its 10-Q filed 2025-08-11.
Financial Statements › Notes › Debt and Equity Securities
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months · last filed 2025-08-11
- 2025-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $239.00M.
- 2024-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $103.72M.
- 2023-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $36.71M.
- 2023-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $104.02M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months |
|---|---|
| 2025-06-30 | $239.00M 10-Q · filed 2025-08-11 |
| 2024-03-31 | $103.72M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $36.71M 10-K · filed 2025-03-03 |
| 2023-09-30 | $104.02M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $170.54M 10-Q · filed 2023-07-31 |
| 2023-03-31 | $213.35M 10-Q · filed 2023-05-12 |
| 2022-12-31 | $187.87M 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |